|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:dextromethorphan
quinidine
|
|
gptkbp:approvalCountry
|
gptkb:United_States
|
|
gptkbp:approvalYear
|
2010
|
|
gptkbp:ATCCode
|
N07XX59
|
|
gptkbp:contraindication
|
concurrent use with MAO inhibitors
prolonged QT interval
hypersensitivity to dextromethorphan
hypersensitivity to quinidine
|
|
gptkbp:drugInteraction
|
gptkb:tricyclic_antidepressants
gptkb:MAO_inhibitors
gptkb:SSRIs
CYP2D6 substrates
|
|
gptkbp:form
|
capsule
|
|
gptkbp:halfLife
|
dextromethorphan: 13-15 hours
quinidine: 6-8 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Nuedexta
|
|
gptkbp:indication
|
gptkb:pseudobulbar_affect
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Avanir_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
CYP2D6 inhibitor (quinidine)
NMDA receptor antagonist (dextromethorphan)
sigma-1 receptor agonist (dextromethorphan)
|
|
gptkbp:notRecommendedFor
|
gptkb:depression
bipolar disorder
schizophrenia
|
|
gptkbp:powers
|
dextromethorphan 20 mg / quinidine 10 mg
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
abdominal pain
dizziness
fatigue
headache
|
|
gptkbp:usedInTreatmentOf
|
neurological disorders with pseudobulbar affect
|
|
gptkbp:bfsParent
|
gptkb:dextromethorphan/quinidine
|
|
gptkbp:bfsLayer
|
7
|